A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels
Open Access
- 8 March 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 104 (7), 1106-1115
- https://doi.org/10.1038/bjc.2011.78
Abstract
Background: Methods: Results: Conclusions:Keywords
This publication has 57 references indexed in Scilit:
- Self-Assembly Synthesis, Tumor Cell Targeting, and Photothermal Capabilities of Antibody-Coated Indocyanine Green NanocapsulesJournal of the American Chemical Society, 2010
- The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunitiesExpert Opinion on Investigational Drugs, 2010
- Anticancer strategies involving the vasculatureNature Reviews Clinical Oncology, 2009
- A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P)Expert Opinion on Investigational Drugs, 2009
- A general method for the selection of high-level scFv and IgG antibody expression by stably transfected mammalian cellsProtein Engineering, Design and Selection, 2008
- Photodynamic Therapy and the Development of Metal-Based PhotosensitisersMetal-Based Drugs, 2008
- Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxelBritish Journal of Cancer, 2007
- Vascular disrupting agents in clinical developmentBritish Journal of Cancer, 2007
- Photodynamic therapy and anti-tumour immunityNature Reviews Cancer, 2006
- Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNature Reviews Drug Discovery, 2004